DE69434724D1 - Bildung, konzentration und effizienter transfer von vsv-g pseudotypisierten retroviralen vektoren - Google Patents
Bildung, konzentration und effizienter transfer von vsv-g pseudotypisierten retroviralen vektorenInfo
- Publication number
- DE69434724D1 DE69434724D1 DE69434724T DE69434724T DE69434724D1 DE 69434724 D1 DE69434724 D1 DE 69434724D1 DE 69434724 T DE69434724 T DE 69434724T DE 69434724 T DE69434724 T DE 69434724T DE 69434724 D1 DE69434724 D1 DE 69434724D1
- Authority
- DE
- Germany
- Prior art keywords
- vectors
- retroviral
- cells
- present application
- cell line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13051—Methods of production or purification of viral material
- C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13061—Methods of inactivation or attenuation
- C12N2740/13062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7320993A | 1993-06-04 | 1993-06-04 | |
US73209 | 1993-06-04 | ||
US104804 | 1993-08-10 | ||
US08/104,804 US5512421A (en) | 1991-02-19 | 1993-08-10 | Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors |
PCT/US1994/006272 WO1994029440A1 (en) | 1993-06-04 | 1994-06-03 | Generation, concentration and efficient transfer of vsv-g pseudotyped retroviral vectors |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69434724D1 true DE69434724D1 (de) | 2006-06-08 |
DE69434724T2 DE69434724T2 (de) | 2007-05-10 |
Family
ID=26754237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69434724T Expired - Lifetime DE69434724T2 (de) | 1993-06-04 | 1994-06-03 | Bildung, konzentration und effizienter transfer von vsv-g pseudotypisierten retroviralen vektoren |
Country Status (7)
Country | Link |
---|---|
US (2) | US5512421A (de) |
EP (1) | EP0702717B1 (de) |
JP (1) | JP3655307B2 (de) |
AT (1) | ATE325187T1 (de) |
AU (1) | AU686181B2 (de) |
DE (1) | DE69434724T2 (de) |
WO (1) | WO1994029440A1 (de) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE263252T1 (de) | 1992-11-09 | 2004-04-15 | Us Health | Erzielbare vektorenpartikel |
JPH10503654A (ja) * | 1994-08-05 | 1998-04-07 | ワーナー−ランバート・コンパニー | レトロウイルスの感染の治療におけるトランスドミナント・ネガティブ・レトロウイルス・インテグラーゼの使用方法 |
US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
EP0796331A2 (de) * | 1994-12-30 | 1997-09-24 | Chiron Corporation | Produktion und darreichung von grossen rangen an rekombinanten retroviren |
US6117681A (en) * | 1995-03-29 | 2000-09-12 | Bavarian Nordic Research Inst. A/S | Pseudotyped retroviral particles |
US5750396A (en) * | 1995-05-08 | 1998-05-12 | St. Judes Children's Research Hospital | Stable virus packaging cell lines |
US5770720A (en) * | 1995-08-30 | 1998-06-23 | Barnes-Jewish Hospital | Ubiquitin conjugating enzymes having transcriptional repressor activity |
US5780448A (en) * | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
CA2237000A1 (en) * | 1995-11-08 | 1997-05-15 | The Whitehead Institute For Biomedical Research | Stable packaging cell line producing pseudotyped retroviruses |
PT870050E (pt) * | 1995-12-29 | 2002-10-31 | Chiron Corp | Virus que expressam proteinas toxicas e linhas de celulas produtoras |
US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
FR2747046B1 (fr) * | 1996-04-05 | 1998-06-19 | Univ Paris Curie | Nouveaux vaccins issus de plasmovirus |
US6133027A (en) * | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
US5739018A (en) * | 1996-08-07 | 1998-04-14 | The Regents Of The University Of California | Packaging cell lines for pseudotyped retroviral vectors |
JPH1080274A (ja) * | 1996-09-06 | 1998-03-31 | Hirofumi Hamada | 核移行シグナルを結合したテトラサイクリン・トランスアクチベーター |
US6818209B1 (en) * | 1998-05-22 | 2004-11-16 | Oxford Biomedica (Uk) Limited | Retroviral delivery system |
US20070213290A1 (en) * | 1996-10-17 | 2007-09-13 | Kingsman Alan J | Neurite regeneration |
GB2337520B (en) * | 1998-05-22 | 2000-06-14 | Oxford Biomedica Ltd | Delivery system |
DE69736163T2 (de) * | 1996-11-04 | 2007-05-03 | Ottawa Health Research Institute, Ottawa | Verfahren zur Expression von Polypeptide in Fischen durch eintauchen in eine plasmid DNA enthaltende Lösung |
CN1059599C (zh) * | 1996-12-27 | 2000-12-20 | 中国科学院水生生物研究所 | 蛙病毒疫苗 |
US6080912A (en) * | 1997-03-20 | 2000-06-27 | Wisconsin Alumni Research Foundation | Methods for creating transgenic animals |
EP0973538B1 (de) | 1997-04-10 | 2008-03-12 | University of Southern California | Sich an extrazelluläre matrixbestandteile anbindende modifizierte proteine |
AU2560999A (en) * | 1998-01-21 | 1999-08-09 | Regents Of The University Of Michigan, The | Targeting gene transfer vectors to certain cell types by pseudotyping with viralglycoprotein |
US6171862B1 (en) | 1998-03-31 | 2001-01-09 | The Regents Of The University Of California | Transfection in serum-containing media |
US20060292121A1 (en) * | 1998-04-29 | 2006-12-28 | Hall Frederick L | Retroviral vectors including modified envelope escort protein |
US7078483B2 (en) * | 1998-04-29 | 2006-07-18 | University Of Southern California | Retroviral vectors including modified envelope escort proteins |
US6448390B1 (en) | 1998-05-20 | 2002-09-10 | The University Of Tennessee Research Corporation | Stable envelope proteins for retroviral, viral and liposome vectors and use in gene drug therapy |
AU5465899A (en) * | 1998-08-04 | 2000-02-28 | Purdue Research Foundation | Pseudotyped retroviruses and stable cell lines for their production |
US7033595B1 (en) | 1998-08-04 | 2006-04-25 | Purdue Research Foundation | Pseudotyped retroviruses and stable cell lines for their production |
GB9904905D0 (en) * | 1999-03-03 | 1999-04-28 | Oxford Biomedica Ltd | Cells |
EP1173551A2 (de) * | 1999-04-23 | 2002-01-23 | Centre for Translational Research in Cancer | Pseudotypisierte retrovirale vektoren zur gentherapie gegen krebs |
KR20070058607A (ko) * | 1999-05-18 | 2007-06-08 | 가부시키가이샤 디나벡크 겐큐쇼 | 엔벨로프 유전자 결손 파라믹소과 바이러스 벡터 |
US6518481B1 (en) * | 1999-08-12 | 2003-02-11 | Exelixis, Inc. | Universal markers of transgenesis |
US20040235173A1 (en) * | 2000-07-03 | 2004-11-25 | Gala Design, Inc. | Production of host cells containing multiple integrating vectors by serial transduction |
US20030224415A1 (en) * | 2001-06-29 | 2003-12-04 | Gala Design, Inc. | Selection free growth of host cells containing multiple integrating vectors |
AU2001271614B2 (en) * | 2000-07-03 | 2007-05-31 | Catalent Pharma Solutions, Llc | Host cells containing multiple integrating vectors |
AU7025201A (en) * | 2000-07-03 | 2002-01-14 | Gala Design Inc | Expression vectors |
US6627442B1 (en) | 2000-08-31 | 2003-09-30 | Virxsys Corporation | Methods for stable transduction of cells with hiv-derived viral vectors |
US20020177571A1 (en) * | 2000-11-29 | 2002-11-28 | Gordon Erlinda M. | Targeted vectors for cancer immunotherapy |
JP2002176880A (ja) * | 2000-12-12 | 2002-06-25 | Kanegafuchi Chem Ind Co Ltd | 効率的な遺伝子導入鳥類の作製法及びそれによって得られる遺伝子導入鳥類 |
US7141649B2 (en) * | 2001-01-26 | 2006-11-28 | Vanderbilt University | Mosquito arrestin 2 polypeptides |
US7166699B2 (en) * | 2001-01-26 | 2007-01-23 | Vanderbilt University | Mosquito arrestin 1 polypeptides |
US7314723B2 (en) * | 2001-01-26 | 2008-01-01 | Vanderbilt University | Method of identifying chemical agents which stimulate odorant receptors of sensory neurons |
US20030026791A1 (en) * | 2001-03-27 | 2003-02-06 | Laurent Humeau | Conditionally replicating vectors for inhibiting viral infections |
CA2344208A1 (en) | 2001-04-30 | 2002-10-30 | Oxford Biomedica (Uk) Limited | Method |
EP1446479B1 (de) | 2001-09-29 | 2012-08-15 | Chae-Ok Yun | Rekombinantes adenovirus mit verstärkter therapiewirkung und das rekombinante adenovirus enthaltende pharmazeutische zusammensetzung |
US20040038304A1 (en) * | 2002-03-28 | 2004-02-26 | Gala Design, Inc. | Antibody libraries |
US7384738B2 (en) * | 2002-03-28 | 2008-06-10 | Bremel Robert D | Retrovirus-based genomic screening |
AU2003237374A1 (en) * | 2002-06-04 | 2003-12-19 | Centers For Disease Control And Prevention | Improved pseudotyped retroviruses |
CA2498297A1 (en) * | 2002-09-09 | 2004-03-18 | University Of Tennessee Research Foundation | Recombinatant mutants of rhabdovirus and methods of use thereof |
US20070178066A1 (en) | 2003-04-21 | 2007-08-02 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
ATE513471T1 (de) * | 2003-04-21 | 2011-07-15 | Epeius Biotechnologies Corp | Verfahren und zusammensetzungen zur behandlung von erkrankungen |
US20090123428A1 (en) * | 2003-04-21 | 2009-05-14 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
WO2004098531A2 (en) * | 2003-05-05 | 2004-11-18 | Virxsys Corporation | Increased transduction using abc transporter substrates and/or inhibitors |
ATE404582T1 (de) * | 2003-06-05 | 2008-08-15 | Wyeth Corp | Immunogene zusammensetzungen, die replikonvektoren des venezolanischen pferdeencephalitisvirus und paramyxovirus- proteinantigene enthalten |
US7696322B2 (en) * | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
US20050100890A1 (en) * | 2003-10-15 | 2005-05-12 | Davidson Beverly L. | Methods for producing and using in vivo pseudotyped retroviruses |
EP1690933B1 (de) * | 2003-11-17 | 2013-04-24 | Eisai R&D Management Co., Ltd. | Herg-kanal exprimierende zelle |
US7135339B2 (en) | 2003-11-20 | 2006-11-14 | University Of Iowa Research Foundation | Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV) |
US20050221429A1 (en) * | 2004-01-16 | 2005-10-06 | Cardinal Health Pts, Llc | Host cells containing multiple integrating vectors comprising an amplifiable marker |
KR101086822B1 (ko) | 2004-09-29 | 2011-11-25 | 다카라 바이오 가부시키가이샤 | 레트로바이러스 벡터 생산용 세포 |
CN101238218A (zh) * | 2005-05-20 | 2008-08-06 | 维克西斯公司 | 初级细胞的转导 |
GB0526210D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Vectors |
US8685720B2 (en) * | 2006-11-03 | 2014-04-01 | The Trustees Of Princeton University | Engineered cellular pathways for programmed autoregulation of differentiation |
DE102006061184A1 (de) | 2006-12-22 | 2008-06-26 | Fresenius Medical Care Deutschland Gmbh | Verfahren zum Primen eines Blutschlauchsatzes |
US8703469B2 (en) | 2007-07-06 | 2014-04-22 | Boyce Thompson Institute For Plant Research | Baculoviruses with enhanced virion production and a method for the production of baculoviruses |
WO2010105020A2 (en) * | 2009-03-13 | 2010-09-16 | Boyce Thompson Institute For Plant Research | Baculoviruses with enhanced virion production and a method for the production of baculoviruses |
US8961951B2 (en) * | 2007-07-06 | 2015-02-24 | Boyce Thompson Institute For Plant Research | Baculoviruses with enhanced virion production and a method for the production of baculoviruses |
JP2011517409A (ja) * | 2008-03-28 | 2011-06-09 | バイレクシス コーポレイション | レンチウイルスベースの免疫原性ベクター |
US20100076061A1 (en) * | 2008-04-30 | 2010-03-25 | University Of Iowa Research Foundation | Repeated administration of lentiviral vectors to respiratory cells |
ES2762864T3 (es) | 2008-06-18 | 2020-05-26 | Oxford Biomedica Ltd | Purificación de virus |
DK2575894T3 (en) | 2010-05-28 | 2015-05-26 | Oxford Biomedica Ltd | FEED lentiviral vectors FOR BRAIN |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (de) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Von einem eingehüllten Virus abgeleitete Virenpartikel |
GB201118636D0 (en) | 2011-10-28 | 2011-12-07 | Oxford Biomedica Ltd | Nucleotide sequence |
GB201202516D0 (en) | 2012-02-13 | 2012-03-28 | Ucl Business Plc | Materials and methods relating to packaging cell lines |
US9347065B2 (en) | 2012-03-29 | 2016-05-24 | International Aids Vaccine Initiative | Methods to improve vector expression and genetic stability |
EP3008192B1 (de) | 2013-06-11 | 2019-07-17 | Takara Bio USA, Inc. | Proteinangereicherte mikrovesikel und verfahren zur herstellung und verwendung davon |
GB201322798D0 (en) | 2013-12-20 | 2014-02-05 | Oxford Biomedica Ltd | Production system |
WO2016210292A1 (en) | 2015-06-25 | 2016-12-29 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
CN109414597A (zh) | 2016-03-09 | 2019-03-01 | 马萨诸塞大学 | 经修饰的hiv-1用于产生完全人抗体的用途 |
WO2017161001A1 (en) | 2016-03-15 | 2017-09-21 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
MX2019011138A (es) | 2017-04-12 | 2020-01-27 | Magenta Therapeutics Inc | Antagonistas del receptor de hidrocarburo de arilo y sus usos. |
WO2019089826A1 (en) | 2017-10-31 | 2019-05-09 | Magenta Therapeutics Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells |
EP3703715A1 (de) | 2017-10-31 | 2020-09-09 | Magenta Therapeutics, Inc. | Zusammensetzungen und verfahren für hämatopoietische stamm- und vorläuferzelltransplantationstherapie |
FI3633040T3 (fi) | 2017-12-22 | 2023-08-03 | Oxford Biomedica Ltd | Retrovirusvektori |
US20200338132A1 (en) | 2018-01-03 | 2020-10-29 | Magenta Therapeutics Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders |
US20210220408A1 (en) | 2018-09-04 | 2021-07-22 | Magenta Therapeutics Inc. | Aryl hydrocarbon receptor antagonists and methods of use |
EP3937985A1 (de) | 2019-03-10 | 2022-01-19 | Sio Gene Therapies Inc. | Gentherapiezusammensetzungen und verfahren zur behandlung von morbus parkinson |
CN114667161A (zh) | 2019-11-12 | 2022-06-24 | 牛津生物医学(英国)有限公司 | 生产系统 |
WO2021160993A1 (en) | 2020-02-13 | 2021-08-19 | Oxford Biomedica (Uk) Limited | Production of lentiviral vectors |
KR20220154734A (ko) | 2020-03-13 | 2022-11-22 | 옥스포드 바이오메디카(유케이) 리미티드 | 렌티바이러스 벡터 |
GB202007199D0 (en) | 2020-05-15 | 2020-07-01 | Oxford Biomedica Ltd | Viral vector production |
GB202017725D0 (en) | 2020-11-10 | 2020-12-23 | Oxford Biomedica Ltd | Method |
GB202114529D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
GB202114534D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Novel viral regulatory elements |
GB202114532D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral Vectors |
GB202114530D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Retroviral vectors |
GB202114528D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
GB202117844D0 (en) | 2021-12-09 | 2022-01-26 | Oxford Biomedica Ltd | Purification method |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1310924C (en) * | 1986-04-24 | 1992-12-01 | Francis P. Mccormick | Infective drug delivery system |
FR2619012B1 (fr) * | 1987-08-07 | 1989-12-22 | Pasteur Institut | Vaccins dont l'epitope caracteristique est incorpore dans une proteine de picornavirus, notamment de poliovirus |
JP2755817B2 (ja) * | 1988-11-14 | 1998-05-25 | アメリカ合衆国 | パルボウイルスキャプシド |
JPH04504361A (ja) * | 1989-04-05 | 1992-08-06 | ノバセル コーポレイション | 感染性標的化複製―欠陥ビリオン |
WO1990015141A2 (en) * | 1989-06-01 | 1990-12-13 | Applied Biotechnology, Inc. | Self-assembled, defective, non-self-propagating viral particles |
EP0487587A1 (de) * | 1989-08-18 | 1992-06-03 | Chiron Corporation | Rekombinante retroviren um vektorkonstruktionen an zielzellen zu liefern |
DE69033710T2 (de) * | 1989-10-24 | 2001-06-13 | Chiron Corp | Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein |
EP1285967A3 (de) * | 1990-09-21 | 2005-03-02 | Chiron Corporation | Humanische Retroviren- Packaging Zellinie |
WO1992014829A1 (en) * | 1991-02-19 | 1992-09-03 | The Regents Of The University Of California | Viral particles having altered host range |
-
1993
- 1993-08-10 US US08/104,804 patent/US5512421A/en not_active Expired - Lifetime
-
1994
- 1994-06-03 EP EP94919349A patent/EP0702717B1/de not_active Expired - Lifetime
- 1994-06-03 DE DE69434724T patent/DE69434724T2/de not_active Expired - Lifetime
- 1994-06-03 AU AU70523/94A patent/AU686181B2/en not_active Expired
- 1994-06-03 JP JP50197495A patent/JP3655307B2/ja not_active Expired - Lifetime
- 1994-06-03 WO PCT/US1994/006272 patent/WO1994029440A1/en active IP Right Grant
- 1994-06-03 AT AT94919349T patent/ATE325187T1/de not_active IP Right Cessation
-
1995
- 1995-06-07 US US08/480,453 patent/US5670354A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP3655307B2 (ja) | 2005-06-02 |
DE69434724T2 (de) | 2007-05-10 |
US5512421A (en) | 1996-04-30 |
AU7052394A (en) | 1995-01-03 |
US5670354A (en) | 1997-09-23 |
WO1994029440A1 (en) | 1994-12-22 |
AU686181B2 (en) | 1998-02-05 |
ATE325187T1 (de) | 2006-06-15 |
JPH08511685A (ja) | 1996-12-10 |
EP0702717A4 (de) | 2000-04-05 |
EP0702717A1 (de) | 1996-03-27 |
EP0702717B1 (de) | 2006-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69434724D1 (de) | Bildung, konzentration und effizienter transfer von vsv-g pseudotypisierten retroviralen vektoren | |
DE68929343T2 (de) | Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen | |
GR3022850T3 (en) | Synthetic DNA derived recombinant HIV-1 antigens | |
DK0500917T3 (da) | Vacciner og fremgangsmåder baseret på rekombinante herpes simplex virusser. | |
CA2104396A1 (en) | Viral particles having altered host range | |
ATE169336T1 (de) | G-csf polypeptide derivatives | |
WO1995006743A3 (en) | Methods and compositions for the large scale production of recombinant adeno-associated virus | |
ATE293171T1 (de) | Retrovirale, mit lcmv-glykoprotein pseudotypisierte hybrid-vektoren | |
PT100245A (pt) | Sequencia de adn que codifica um derivado de factor viii humano recombinante, biologicamente activo, vector de expressao recombinante, celula hospedeira, processo de producao de um derivado de factor vii e derivado de factor viii | |
DK355486A (da) | Fusionsproteiner, deres fremstilling og anvendelse | |
KR900700592A (ko) | 용해성 티-4 유도체 | |
DE69334350D1 (de) | P- Selectin Ligandenprotein | |
DK192189A (da) | Polypeptid, fremgangsmaade til inhibering af fibrinogen, fremgangsmaade til rensning af et polypeptid, gen indeholdende rekombinante dna kodende for et polypeptid, vektor, cellekultur og fremgangsmaade til fremstilling af et cysteinrigt polypeptid | |
DK0386752T3 (da) | Polypeptid og fremstilling heraf | |
DE3856240T2 (de) | Herstellung der p1 proteine und impfstoffe gegen gonorrhöe | |
CA2019803A1 (en) | Feline interferon and process for production thereof | |
DE69318716T2 (de) | Anti-Katze Immundefiziensvirus (FIV) Impfstoffe | |
CA2164324A1 (en) | Generation concentration and efficient transfer of vsv-g pseudotyped retroviral vectors | |
EP0432220A4 (en) | Vaccines and diagnostic assays for haemophilus influenzae | |
ATE43139T1 (de) | Klonierungs- und expressionsvektoren fuer gammainterferon, transformierte bakterien und verfahren zur herstellung von gamma-interferon. | |
Hantula et al. | Chemical crosslinking of bacteriophage φ6 nucleocapsid proteins | |
Thornton et al. | Microinjection of vesicular stomatitis virus ribonucleoprotein into animal cells yields infectious virus | |
SU1380209A1 (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК PUR 291-HAV 22, КОДИРУЮЩАЯ СИНТЕЗ ГИБРИДНОГО ПОЛИПЕПТИДА АНТИГЕННЫХ ДЕТЕРМИНАНТ ВИРУСА ГЕПАТИТА А С β -ГАЛАКТОЗИДАЗОЙ | |
RU93058018A (ru) | Рекомбинатная плазмидная дик pgdn, определяющая синтез гибридного белка, обладающего антигенными свойствами вируса т-клеточного лейкоза человека i типа, способ ее конструирования и штамм бактерий escherichia coli - продуцент гибридного белка, обладающего антигенными свойствами вируса т-клеточного лейкоза человека 1 типа (нтlv-i) | |
SU1515698A1 (ru) | Рекомбинантная плазмидная днк, кодирующая синтез hbs ag вируса гепатита b, и штамм вируса осповакцины - продуцент hbs ag вируса гепатита b |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |